Amivantamab Plus Lazertinib Shows Promising Activity in Atypical EGFR-Mutant Advanced NSCLC: CHRYSALIS‑2 Cohort C Results
In CHRYSALIS‑2 Cohort C, the amivantamab plus lazertinib combination produced a 52% ORR and durable responses (mDoR 14.1 months) in advanced NSCLC with atypical EGFR mutations, with higher activity in treatment‑naïve patients and an expected safety profile.
